{"created":"2021-03-01T06:17:33.136182+00:00","id":13212,"links":{},"metadata":{"_buckets":{"deposit":"dd8cbb08-f0c2-4d3a-a5ac-53db0ea861d7"},"_deposit":{"id":"13212","owners":[],"pid":{"revision_id":0,"type":"depid","value":"13212"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00013212","sets":["453:456","471:537:538:1041"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Monitoring of Serum 5-FU Concentrations During Pharmacokinetic Modulating Chemotherapy for Recurrent Colorectal Cancer"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2004-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"161","bibliographicPageStart":"157","bibliographicVolumeNumber":"118","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【目的】Pharmacokinetic modulating chemotherapy (PMC療法)は血清5-FU濃度を高濃度に保つことにより,高い抗腫瘍効果を得る治療法である.本研究の目的は,PMC療法中の血清5-FU濃度の推移を明らかにすることである.【方法】対象は大腸癌術後再発7症例であり,全例が評価可能な再発病変を有していた.原発部位は結腸5例,直腸2例であり,再発部位は肝+肺3例,肝+肺+リンパ節1例,腹膜単独2例,リンパ節単独1例であった.PMC療法(週1回の5-FU600～900mg/m^2/24h持続静注およびUFT400mg/dayの週5～7日間経口投与)を施行し,5-FUの24h持続静注時の血清5-FU濃度を測定した(HPLC法).【成績】7症例におけるPMC療法の施行期間は6～15か月(中央値10か月)であった.PR5例,NC2例(内1例MR)であり,6例で腫瘍が縮小した.肝+肺再発の2例,肝+肺+リンパ節再発の1例および腹膜単独再発の2例ではPRが得られた.Grade2以上の副作用は認められなかった.PMC療法(5-FU投与量600mg/m^2/24h)中の血清5-FU濃度は,日中低く夜間に最高値(153～313ng/ml,中央値240ng/ml)となった.【結語】大腸癌術後再発に対しPMC療法は有効である.PMC療法中の血清5-FU濃度の推移は,日中低く夜間に最高値となる.PMC療法の有効性は,夜間の高い血清5-FU濃度によるものと考えられる.","subitem_description_type":"Abstract"}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宗岡, 克樹"}],"nameIdentifiers":[{"nameIdentifier":"87125","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"白井, 良夫"}],"nameIdentifiers":[{"nameIdentifier":"87126","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"横山, 直行"}],"nameIdentifiers":[{"nameIdentifier":"87127","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"若井, 俊文"}],"nameIdentifiers":[{"nameIdentifier":"87128","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"畠山, 勝義"}],"nameIdentifiers":[{"nameIdentifier":"87129","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須田, 剛士"}],"nameIdentifiers":[{"nameIdentifier":"87130","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"青柳, 豊"}],"nameIdentifiers":[{"nameIdentifier":"87131","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"KJ00004351504.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00004351504.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/13212/files/KJ00004351504.pdf"},"version_id":"4efb8c87-7b59-4c8a-96da-00a3b244b93d"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Pharmacokinetic Modulating Chemotherapy (PMC療法)施行中の血清5-FU濃度 : 大腸癌術後再発症例における検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Pharmacokinetic Modulating Chemotherapy (PMC療法)施行中の血清5-FU濃度 : 大腸癌術後再発症例における検討"},{"subitem_title":"Pharmacokinetic Modulating Chemotherapy (PMC療法)施行中の血清5-FU濃度 : 大腸癌術後再発症例における検討","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1041"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-05-10"},"publish_date":"2007-05-10","publish_status":"0","recid":"13212","relation_version_is_last":true,"title":["Pharmacokinetic Modulating Chemotherapy (PMC療法)施行中の血清5-FU濃度 : 大腸癌術後再発症例における検討"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:45:46.266172+00:00"}